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Abstract The cystic phenotype in autosomal dominant
polycystic kidney disease is characterized by a profound
dysfunction of many cellular signaling patterns, ultimately
leading to an increase in both cell proliferation and apop-
totic cell death. Disturbance of normal cellular Ca2?
signaling seems to be a primary event and is clearly
involved in many pathways that may lead to both types of
cellular responses. In this review, we summarize the current
knowledge about the molecular and functional interactions
between polycystins and multiple components of the cel-
lular Ca2?-signaling machinery. In addition, we discuss the
relevant downstream responses of the changed Ca2? sig-
naling that ultimately lead to increased proliferation and
increased apoptosis as observed in many cystic cell types.
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD)
affects more than 1 in 1,000 live births and is the most
common monogenic cause of kidney failure in humans
[1–4]. ADPKD is characterized by the progressive forma-
tion and enlargement of renal cysts, typically leading to
chronic renal failure by late middle age. In most cases, the
disease arises as a consequence of mutations in the PKD1 or
PKD2 genes, which encode the proteins polycystin-1 and -2,
respectively. Mutations in the PKD1 gene account for
approximately 85 % (ADPKD type 1), and mutations in the
PKD2 gene account for approximately 15 % (ADPKD type
2) of the affected individuals [2]. Disease progression is
typically more rapid in ADPKD type 1, with a mean age of
end-stage renal disease approximately 20 years earlier than
in type 2, but in all other respects ADPKD types 1 and 2
share almost identical disease phenotypes. This suggests
that polycystin-1 and -2 function in common pathways,
implying that loss of activity of either protein results in a
very similar disease manifestation [5]. The biological role of
the polycystin proteins and the molecular basis by which
mutational malfunction of either of them leads to cysto-
genesis, have proven to be very complex, and have been
discussed in several recent reviews [1, 2, 6–13]. A widely
accepted view is that polycystin-1 and -2 are functionally
associated in a receptor-ion channel complex, in which
polycystin-1 acts as a receptor that gates the Ca2?-perme-
able polycystin-2 channel [14, 15]. Polycystin-1 (4,302
amino acids) contains a large extracellular N-terminal
domain, 11 predicted transmembrane spanning segments,
and an intracellular C-terminus [16]. The extracellular
region of polycystin-1 contains [3,000 amino acids and is
implicated in cell–cell and cell–matrix interactions. Poly-
cystin-1 is cleaved at its predicted G-protein-coupled
receptor proteolytic site, a feature that could be essential for
its biological activity [17]. The intracellular C-terminus of
polycystin-1 contains a coiled-coil domain that is involved
in the physical interaction with other proteins, and in par-
ticular with polycystin-2 [18, 19]. Polycystin-2 is a smaller
transmembrane protein (968 amino acids) predicted to
have six transmembrane regions and sharing significant
homology with transient receptor potential (TRP) channels
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[9, 12, 13, 20]. Better understanding of the role of the
polycystin-1/polycystin-2 complex came from the obser-
vation that this co-assembly produced cation-permeable
currents at the plasma membrane [21], and participated in
mechano-sensation and flow-dependent Ca2? signaling in
the primary cilium [22]. As reviewed recently, there is a
clear connection between polycystic kidney disease and
dysfunction of ciliary proteins [13]. The precise cellular
function of the polycystin proteins is, however, still not
completely understood, particularly as both polycystins
have been found in cellular locations other than the cilium
[23]. Polycystin-1 has been localized to cell–cell junctions
and both apical and basolateral membranes [23, 24]. Poly-
cystin-2 is a resident endoplasmic-reticulum (ER) protein
[25] and its trafficking is highly regulated [26–29]. The
differential localization of both polycystins also suggests
that these proteins may display different cellular functions
either alone or as a protein complex [29, 30]. Several
cellular mechanisms have been proposed to explain cyst
formation and cyst growth including a change in cell
polarity [31], an altered matrix composition [32], and
remarkably, a disturbed balance between cell proliferation
and apoptosis [33]. The view that polycystin-2 is a potential
Ca2? channel and polycystin-1 is a receptor regulating its
activity, suggests that intracellular Ca2? signaling could be
one of the most proximal events in many cellular functions
of the polycystins and consequently in the dysfunctional
mechanisms that may lead to cyst formation. Clearly, the
Ca2? effects are not limited to the restricted compartment of
the cilium but will also involve Ca2? influx from other parts
of the plasma membrane as well as Ca2? release from the
ER. The situation becomes even more complex as polycy-
stin-2 was found to associate with other Ca2? channels in the
plasma membrane (TRPC1 [34, 35] and TRPV4 [36]), and
in intracellular membranes (inositol 1,4,5-trisphosphate
receptor (IP3R) [37, 38] and ryanodine receptor (RyR) [39]).
Moreover, polycystin-1 has been found to interact with basic
components of the Ca2? toolkit such as the IP3R [40] and the
stromal interaction molecule-1 (STIM1) [41]. Hence,
polycystins may affect Ca2? signaling in many different
ways, including effects on cytosolic or ER Ca2? concentra-
tion, global or local Ca2? changes, Ca2? oscillations,
intracellular Ca2?-leak pathways or plasma-membrane Ca2?
influx or a combination of these effects. However, the cellular
role of polycystins in Ca2? signaling, and the downstream
parameters that may link the disturbed Ca2? signaling in
ADPKD to cyst formation, are not yet understood [42]. In this
review, we provide an update of the different effects of
polycystins on cellular Ca2? signaling. We also discuss the
current view on the downstream signaling pathways that
could be affected by the dysfunctional Ca2? signals in
ADPKD, ultimately leading to a cystic phenotype with
increased proliferation and increased apoptosis.
Disturbed cellular Ca21 fluxes in ADPKD
Cilium and plasma membrane
Polycystin-1 and -2 can form heteromeric complexes
in vivo [43]. Importantly, co-expression of both proteins in
Chinese hamster ovary (CHO) cells promoted the translo-
cation of polycystin-2 to the plasma membrane and the
complex produced a Ca2?-permeable non-selective cation
channel [21]. Neither of the polycystins alone produced an
ion current, while disease-associated mutants that are
incapable of heterodimerization did not result in channel
activity. Heterologous expression of both proteins resulted
in the formation of a plasmalemmal ion-channel complex
in neurons as well as in kidney cells, in which polycystin-2
activation occurred through structural rearrangement of
polycystin-1 [14]. An important finding was that both
proteins co-localize in the primary cilia of epithelial cells,
where their role could be to promote mechano-sensation
and fluid-flow sensation [22, 44] (Fig. 1). Cells isolated
from transgenic mice that lack functional polycystin-1
formed cilia, but did not increase Ca2? influx in response to
physiological fluid flow. Inhibitory antibodies directed
against polycystin-2 similarly abolished the flow response
in wild-type cells. Defects in proteins involved in the
function or structure of primary cilia such as cystin, polaris,
inversin, and kinesin-II also cause polycystic kidney dis-
eases [45]. Fluid shear-force bending of the cilium causes
the influx of Ca2? through mechanically sensitive channels
in the ciliary membrane [46]. The Ca2? signal could then
be further amplified by Ca2? release from IP3Rs or RyRs
via a Ca2?-induced Ca2?-release (CICR) mechanism. This
view proposes a dysregulated Ca2? influx as an important
first step in the initiation of cystogenesis [47].
There has been some confusion regarding the structural
model for the polycystin-1/-2 complex. A newly identified
coiled-coil domain in the C-terminus of polycystin-2 (a.a.
839–873), different from a more upstream coiled-coil
domain (a.a. 772–796) [19], has been proposed to mediate
assembly into a homotrimer to which a single coiled-coil
domain in the C-terminus of polycystin-1 (a.a. 4214–4248)
can bind [48, 49]. Other evidence, obtained by atomic force
microscopy, however, showed that the polycystin-1/-2
complex assembles as a tetramer with a 2:2 stoichiometry
[50]. The latter is more in line with recently described
homo- and heteromeric polycystin-2 channel properties
suggesting fourfold symmetry [35, 36, 51]. Differences
between both models may be due to different structural
properties of the helix containing a coiled-coil-domain
motif, which may oligomerize differently as an isolated
peptide than when embedded in the folded protein [52].
Deletion of this polycystin-2 coiled-coil domain (referred to
as CC2 domain) indicated that although this domain is
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required for heterotypic interaction with polycystin-1, it
does not represent the binding site itself [52]. In agreement
with earlier studies [19, 48], the domain responsible for
binding was found distal from CC2 (a.a. 872–895). Fur-
thermore, there is evidence for a dimerization site in
polycystin-2, N-terminally located of the first transmem-
brane domain, which regulates channel tetramerization
[53]. Although CC2 is considered an assembly domain, it
does not seem to have a prominent role in the self-associ-
ation of polycystin-2 [52]. Polycystin-2 channels with CC2
deletions still tetramerize [52], and C-terminal mutants can
co-immunoprecipitate full-length polycystin-2 [53]. The
role of the C-terminus of polycystin-2 may therefore be to
provide an essential scaffolding platform for heteromeric
assembly with other channel proteins, including polycystin-
1 [19], TRPC1 [34], TRPV4 [36], and the IP3R [37].
The polycystin-2 C-terminus is important for the regu-
lation of the Ca2?-channel activity [54–56]. An EF-hand
motif was identified connected by a linker to a coiled-coil
domain overlapping with CC2 [54]. An affinity for Ca2? in
the micromolar range was found for the EF-hand domain
by isothermal titration calorimetry. This region may
therefore sense local Ca2? concentration changes and






































Fig. 1 Major players controlling cellular Ca2? signaling by polycys-
tins. Polycystin-1 (PC1) and polycystin-2 (PC2) form a signaling
complex in the cilium that mediates Ca2? influx via PC2, possibly in
response to mechanical stimuli. Also TRPV4, TRPC1, and TRPC4
interact with PC2 and could play a role in mechano-sensitive Ca2?
influx. PC2 is also present in the ER where it directly interacts with
the IP3R and in cardiac cells also with the RyR2. PC2 behaves as a
Ca2?-induced Ca2?-release channel and thereby amplifies IP3-
induced Ca2? release. The RyR2 is activated by Ca2? influx via
voltage-operated Ca2? channels and is inhibited by PC2. Ca2? leak
via PC2 may be controlled by other proteins such as syntaxin-5. PC1
activates the PI3-K/AKT signaling. This leads (by as-yet-unresolved
mechanisms) to an increase in the STIM1-IP3R interaction, which
reduces the interaction between the IP3R and PC2 with possibly a
translocation of PC2 to the plasma membrane. PC1 and PC2 compete
for the same binding site on the IP3R. PC1 dysfunction leads to
strengthening of the IP3R-PC2 interaction and remodeling of the Ca
2?
fluxes with an increase of IICR, more ER Ca2? depletion, and Ca2?
influx via activation of SOCE. PC1 also negatively modulates
agonist-evoked NCCE activity through a still undefined mechanism.
Loss of function of PC1 causes an increase in NCCE-channel activity
leading to Ca2? oscillations. PC1/PC2 polycystin-1/-2, NCCE non-
capacitive Ca2? entry, DV voltage change over the plasma membrane,
VOCC voltage-operated Ca2? channel. Inhibitory and stimulatory
mechanisms are represented by red and green arrows, respectively;
the purple arrow represents the trafficking of PC2; dotted lines
indicate that the mechanisms are as yet undefined
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folding and oligomerization of polycystin-2 [54] and sub-
sequent channel gating [56].
Polycystin-2 can form spontaneously active nonselec-
tive cation channels in lipid bilayers [35, 57, 58]. Analysis
of the channel properties revealed a high-conductance,
nonselective, voltage-dependent cation channel [58]. Using
various organic cations of different size, the pore diameter
was estimated to be at least 1.1 nm [59]. Heterologous
expression in Xenopus oocytes revealed a channel that is
sensitive to changes of the cytosolic Ca2? concentration
[60]. Spontaneous activity of polycystin-2 was, however,
not always obtained upon heterologous expression of
polycystin-2 and polycystin-1 [48], which clearly illus-
trates the difficulty in identifying the physiological
activation mechanisms of polycystin-2 or of the polycystin-
1/-2 complex. An even larger complexity is suggested from
the observations that polycystin-2 may associate and per-
haps form heteromeric channels with other TRP-family
members such as TRPC1 [34, 35, 51], TRPC4 [61], and
TRPV4 [36] (Fig. 1). The function and regulation of
polycystin-2 at the plasma membrane downstream of
mechanical stimulation, cell-surface receptors, and cell
adhesion, were recently discussed in an excellent review
[12]. A role for polycystin-2 as a mechanosensitive channel
has been suggested from measurements of changes in the
cytosolic Ca2? concentration in response to fluid flow [22,
62–64]. Also, regulation of polycystin-2-channel activity
by environmental signals such as hydrostatic and osmotic
pressure [65] and by cytoskeletal [66] and microtubular
[67] elements in the human syncytiotrophoblast supports
such a role. Mechanosensitivity of polycystin-2 may result
from its interaction with TRPV4, which was required for
fluid flow-induced Ca2? entry in Madin–Darby canine
kidney (MDCK) cells [36]. Loss of TRPV4, however, did
not result in cyst formation, which suggests that mecha-
nosensitive activation of this channel complex alone is not
sufficient for cyst formation [36]. Polycystin-2 can also
function as a bona fide receptor-operated channel down-
stream of epidermal growth factor (EGF) receptor
activation [68]. EGF-induced activation of polycystin-2
required the activation of phospholipase C (PLC). Poly-
cystin-2 interacted with PLC-c2 and colocalized in the
primary cilium with the EGF receptor and phosphatidyl
inositol 4,5-bisphosphate (PIP2) [68]. EGF-induced acti-
vation of PIP2 breakdown resulted in the relieve of PIP2-
mediated inhibition of polycystin-2 [68]. The localization
of the EGF receptor in the primary cilium could represent a
sensitization of the polycystin-2-channel activity with
implications for cilium-based mechano-transduction, as it
may reduce its threshold for activation by mechanical
stimulation [12]. Channel activity of polycystin-2 com-
plexed with TRPC1 but not with polycystin-1 could also be
activated in response to PLC-coupled bradykinin-receptor
stimulation [51]. This polycystin-2/TRPC1 channel with
distinct properties from the polycystin-1/-2 complex has
implications in mechano-sensation and cilium-based Ca2?
signaling [51]. Homologs of polycystin-1 and -2 have been
shown to form receptor channel complexes acting as sour-
taste receptors [69]. As there is increasing evidence from
several gene-inactivation studies indicating that cilium-
mediated mechano-transduction is not alone responsible
for cyst formation, receptor-operated activation may play
an important role [36, 51, 70–72]. A combined mechanism
of flow-dependent delivery of a ligand would thereby
become an intriguing possibility [13].
Intracellular membranes
The intracellular distribution of polycystin-2 is very com-
plex, with the largest pool in the ER in addition to its
localization at the plasma membrane and in more restricted
domains such as the primary cilium and mitotic spindles as
discussed in several reviews [3, 27, 73]. Next to its role as a
plasma-membrane Ca2? channel and its ciliary function in
complex with polycystin-1, polycystin-2 was proposed to
have a function in intracellular Ca2? release [25, 58]. Other
findings, however, suggested that whereas heterologous
expression of polycystin-2 showed a predominant ER
localization, endogenous polycystin-2 was found primarily
in the cilium and plasma membrane of mouse inner med-
ullary collecting duct (IMCD) cells and in MDCK cells
[74]. The long-standing controversy about this differential
distribution has been clarified to some extent by the iden-
tification of specific signal sequences and trafficking
proteins [3, 30, 60, 75]. A stretch of acidic amino acids in
the C-terminus of polycystin-2 functions as an ER-reten-
tion signal by binding phosphofurin acidic cluster-sorting
proteins (PACS-1 and -2) [25, 28]. Binding of PACS-1 and
PACS-2 requires polycystin-2 phosphorylation by casein
kinase II (CK-II) at Ser 812, and mediates retrieval back to
the trans-Golgi network (PACS-1) and the ER (PACS-2),
respectively [28]. Prevention of this phosphorylation in the
Caenorhabditis elegans polycystin-2 homologue promoted
its translocation to the cilium [76]. Polycystin-2 interactor
Golgi- and ER-associated protein (PIGEA-14) is another
regulator of polycystin-2 trafficking, causing its movement
to a putative trans-Golgi compartment [77]. Plasma-mem-
brane, but not cilia, localization of polycystin-2 is regulated
by glycogen synthase kinase 3 (GSK3) phosphorylation of
Ser 76 in the N-terminus [78]. In the presence of specific
GSK3 inhibitors, the lateral plasma-membrane pool of
endogenous polycystin-2 redistributes into an intracellular
compartment in MDCK cells without any change in pri-
mary-cilia localization [78]. Furthermore, the N-terminus
of polycystin-2 contains a motif (R6V7xP8), which is
required for localization in the cilia [79]. Cyst cells
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expressing an ADPKD-associated polycystin-1 mutant had
decreased amounts of both polycystin-1 and -2 in the pri-
mary cilium, indicating that impairing the function of one
protein negatively affects the localization of the other [80].
An interaction between the C-termini of polycystin-1
and polycystin-2 is considered to be important for activa-
tion of the Ca2?-channel activity [14, 21]. This does not
necessary require a co-localization in the same membrane,
and a model for interaction with polycystin-2 either
localized in the plasma membrane or in the ER has been
proposed [47, 81]. The concept that polycystin-2 may be a
novel type of intracellular Ca2?-release channel was based
on the observation that polycystin-2 exogenously expressed
in LLC-PK1 epithelial cells caused a marked augmentation
of intracellular Ca2? release upon vasopressin stimulation
[58]. A similar role as an intracellular Ca2?-release channel
was also found for the endogenous homologue of polycy-
stin-2 in Caenorhabditis elegans [82]. The open probability
of the channel was increased by Ca2? in the physiological
range (0.1–10 lM), whereas higher cytosolic [Ca2?] low-
ered the open probability [58]. The observation that
polycystin-2 may function as a CICR channel was further
strengthened by the sensitization towards Ca2? upon CK-II
phosphorylation at the C-terminal S812 site [83]. Polycy-
stin-2-mediated Ca2? release from the ER required
activation of the IP3R [37, 58]. Moreover, it was demon-
strated that polycystin-2 and the IP3R physically interact
and the C-terminus of polycystin-2 is required for this
interaction [37] (Fig. 1). The binding site was further
identified as the acidic cluster in the C-terminus of poly-
cystin-2, which interacts with a cluster of basic residues in
the N-terminal suppressor domain of the IP3R [38]. Dis-
ruption of this molecular interaction by using competitive
peptides eliminated the stimulation of IP3-induced Ca
2?
release (IICR) by polycystin-2. In both studies, the channel
death mutant (D511 V) did not provoke stimulation of
IICR, which is a strong indication that polycystin-2 oper-
ates as a CICR channel that becomes activated by IICR in
the immediate proximity of the IP3R-channel pore. Acti-
vation appears to be restricted to a microdomain of IICR as
reduction of this microdomain by the fast Ca2? buffer
BAPTA eliminated activation of the CICR via polycystin-
2, whereas the slower Ca2? buffer EGTA did not have such
effect [38]. It is conceivable that ER-localized polycystin-2
is silent in resting conditions as inappropriate opening of
this channel would represent a Ca2? leak from the ER
eventually resulting in ER depletion and an ER-stress
response [84]. At variance with these data, it was observed
that exogenous expression of polycystin-2 in HeLa cells
increased the ER Ca2? permeability, which resulted in
lowering of the ER Ca2? content and a decrease in the
histamine-evoked Ca2? response [85]. The IP3R was not
required for the polycystin-2-mediated reduction of the ER
Ca2? load, which suggested that polycystin-2 forms an
independent ER Ca2?-leak channel [85]. The apparently
contradictory results regarding amplification of IICR as a
result of CICR via polycystin-2 [37, 38, 58], versus a
diminished IICR due to ER Ca2?-store depletion [85], can
possibly be reconciled by the cell- and condition-specific
factors that regulate activation of polycystin-2 in the ER.
Syntaxin-5, an ER- and Golgi-associated t-SNARE that
functions in vesicle targeting and fusion, was found to
directly interact with polycystin-2 and to inactivate its
channel activity [86]. Syntaxin-5 was proposed to have a
function in preventing the Ca2? leak from the ER via
polycystin-2. LLC-PK1 cells expressing D(5–72) polycy-
stin-2 that lacks the syntaxin-5-binding site had a reduced
ER Ca2? content and a concomitant lower increase in
cytosolic [Ca2?] upon agonist stimulation [86]. Polycystin-
2 in the ER may therefore play an important role for
controlling ER Ca2? levels and its activity may be tightly
controlled. Among the other polycystin-2-interacting pro-
teins, polycystin-1 [87], a-actinin [88], mammalian
diaphanous-related forming 1 (mDIA-1) [89], and fibro-
cystin [90] have been found to modulate polycystin-20s
activity.
Polycystin-2 was also found to bind and regulate the
RyR2 in the sarcoplasmic reticulum (SR) of cardiac myo-
cytes [39]. The C-terminus of polycystin-2 functionally
inhibited the RyR2 channel and polycystin-2-deficient
cardiomyocytes showed changes in store content and Ca2?-
release properties. This altered RyR2 function could play a
role in the development of cardiovascular abnormalities in
ADPKD patients [39].
On the one hand, polycystin-2 can act as a regulator of
other ER/SR channels, but on the other hand, it has its own
channel properties that may be controlled by different cel-
lular parameters. An obvious candidate for the regulation of
polycystin-20s channel properties in the ER is polycystin-1.
As stated above, models were proposed for interaction of
polycystin-1 in the plasma membrane with polycystin-2 in
the ER [47, 81]. Although it is still unclear what the func-
tion could be of polycystin-1 at the level of the ER, there is
compelling evidence that a significant amount of polycy-
stin-1 is also localized there [43, 91]. This is particularly the
case for shorter C-terminal cleavage forms, which were
shown to functionally interact with the IP3R thereby
inhibiting IICR [40]. The interaction site was found to be
the IP3R ligand-binding domain similarly to the binding site
for polycystin-2 but with an opposite effect. It was therefore
proposed that polycystin-1 and polycystin-2 both interact
with the IP3R in a complementary way to maintain a bal-
ance of proper ER-mediated Ca2? signaling [40]. A
different result was obtained by other authors [92], showing
that exogenous expression of polycystin-1 in MDCK cells
accelerated the decay of ligand-activated cytoplasmic Ca2?
Polycystins and cellular Ca2? signaling 2701
123
transients. These data were interpreted as due to an inhibi-
tion of the Ca2? leak across the ER membrane. These
studies clearly illustrate the importance of polycystins in
maintaining proper ER Ca2? homeostasis [93]. Another
unexpected finding, consistent with the reduction of the
intracellular Ca2? responses, was the identification of a
P100 C-terminal fragment of polycystin-1 that is localized
in the ER and interacts with STIM1 [41]. P100 probably
contains the six C-terminal transmembrane domains and the
C-terminal tail. It would interact with STIM1 via its coiled-
coil domain and thereby interfere with the translocation of
STIM1 to the plasma membrane, inhibiting the activation of
store-operated Ca2? currents. This would then lead to
decreased store filling and subsequently to diminished
agonist-induced Ca2? transients [41]. It should be noted,
however, that the expression of the C-terminal tail of
polycystin-1 as a fusion protein yielded an opposite result
and led to an increase in the cytosolic Ca2? concentration
and store-operated Ca2? entry (SOCE) [94, 95]. This dis-
crepancy may be due to a dominant negative effect of the
polycystin-1 C-terminus, given the observation that the
formation of P100 actually requires the presence of full-size
polycystin-1 [41]. The nature of the polycystin-1 cleavage
responsible for P100 generation and the significance of this
mechanism are as yet unknown, but these findings clearly
illustrate the importance of polycystin-1 as well as
polycystin-2 for ER Ca2? signaling. Mechanistically,
polycystin-1 was proposed to increase the interaction
between the IP3R and STIM1, which thereby inhibited Ca
2?
release and SOCE [96] (Fig. 1). This regulation implicated
the activation of the phosphatidylinositol 3-kinase (PI3-K)/
protein kinase B (AKT) signaling pathway and would act
upon a protein complex involving polycystin-2/IP3R/
STIM1. It should be pointed out, however, that in a study
comparing STIM1-/- and wild-type MEF cells, no evi-
dence was found for a direct interaction between STIM1
and the IP3R, but the effects on IICR were attributed to
changes in the connections between the ER and plasma
membrane [97].
The effects of polycystin-1 on ER Ca2? release were
mostly obtained by exogenous expression of polycystin-1
or its C-terminal fragments. The properties of endogenous
polycystin-1 as obtained from knock-down experiments are
much less documented. In studies of polycystin-1 hap-
loinsufficiency in renal cells [98] or in vascular cells [99],
the results pointed to a decreased resting cytosolic Ca2?
concentration in the polycystin-1?/- as compared to the
wild-type cells. Moreover, vascular smooth-muscle cells
from polycystin-1?/- mice exhibited a decreased agonist-
induced Ca2? release as compared to the wild type [99].
This result is in contrast to the data obtained with exoge-
nous polycystin-1 expression, but it is more in line with the
general concept that polycystin-1 and polycystin-2 form a
functional complex with Ca2?-channel properties. Distur-
bance of this complex by either polycystin-2 or polycystin-
1 knock-out is then expected to result in a decreased Ca2?-
release activity. This is exactly what was recently found for
the effect on IICR in a model system of plasma membrane-
permeabilized cells upon lentiviral knock-down of either or
both polycystins [100]. The presence of both polycystins
seemed to be required for stimulation of Ca2? release from
the ER and knock-down of either polycystin decreased the
apparent sensitivity of IICR [100]. The conflicting results
from different groups may be caused by the fact that on the
one hand exogenous expression may result in abnormal
processing, trafficking and localization, and on the other
hand knock-out or knock-down of endogenous genes may
result in adaptive responses. For both approaches, the
unraveling of the detailed mechanism is presently not at
hand, but it becomes increasingly clear that both polycys-
tins are implicated in ER-related Ca2? fluxes. An
interesting view that was presented in a model by the
Guggino group [96], proposed a role for polycystin-1 in
preventing a phenotype with more IICR and SOCE-medi-
ated Ca2? fluxes and promoting a situation with more filled
stores and inactivated SOCE with Ca2? influx via plasma
membrane (or cilia)-localized polycystin-2 (Fig. 1). While
not all data are easily reconciled with this model, it pre-
sents the very appealing idea that defective polycystins in
ADPKD provoke a shift in the spatial properties of intra-
cellular Ca2? signals with the appearance of different
microdomains with altered cytosolic Ca2? concentrations,
which can then elicit different downstream effects.
Downstream effects of Ca21 signaling in ADPKD
Effects on cAMP signaling
Disturbed Ca2? signaling is a proximal event in ADPKD
and it directly or indirectly affects several other very
important signaling pathways [101]. Among these, an
increased cAMP concentration is a common finding in
different models of ADPKD and cAMP stimulates cyst
fluid and electrolyte secretion [102], possibly involving the
stimulation of the cystic fibrosis transmembrane conduc-
tance regulator (CFTR) [103]. The reasons for the high
cytosolic cAMP concentration in cyst cells are not very
well understood. The polycystin proteins may alter the
activity of G-protein-coupled receptors, like the V2 vaso-
pressin receptor, that signal via cAMP [102, 104]. A link
with cellular Ca2? homeostasis was proposed via the
activity of Ca2?-inhibitable adenylyl cyclase (AC) and/or
Ca2?-dependent phosphodiesterase (PDE) [101]. The
interaction between cytosolic Ca2? and cAMP is, however,
very complex, as there are nine different genes encoding
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transmembrane-domain ACs (AC1–9) along with numer-
ous splice variants of the gene encoding soluble ACs, while
also the cyclic nucleotide-PDE superfamily consists of
over 30 genes [105]. Moreover, different members of these
families are sensitive to Ca2?, either directly or via cal-
modulin. A common theme in the regulation of cAMP
production is the pronounced intracellular compartmen-
talization. Three modes of cAMP microdomain/
compartment formation are found: via (a) lipid rafts,
(b) A-kinase anchor proteins (AKAPs), and (c) targeting of
soluble AC to cellular organelles [105]. It can therefore be
anticipated that a relation between polycystin dysfunction
and the cAMP levels in ADPKD may be very much linked
to specific microdomains either at the plasma membrane or
at intracellular membranes and may involve particular AC
or PDE isoforms. In this respect, it was recently demon-
strated that the primary cilium plays an important role as a
subcellular cAMP-signaling compartment [106]. A protein
complex comprising AKAP150, AC5/6, and protein kinase
A (PKA) was found in primary cilia of renal epithelial
cells. Polycystin-2 and PDE4C were further identified as
components of this ciliary AKAP complex. Under normal
conditions PDE4C would promote the hydrolysis of cAMP
and polycystin-2 could provide local accumulation of Ca2?
that inhibits the Ca2?-sensitive AC5 and AC6. Malfunction
of polycystin-2 as a Ca2? channel may reduce the local
Ca2? concentration in the cilium and thereby activate AC5/
6. Other mechanisms like mutations of the transcription
factor hepatocyte nuclear factor-1ß (HNF-1ß) were found
to inhibit the expression of PDE4C and thereby increase
cAMP levels [106]. As HNF-1ß also regulates the
expression of Pkd2 itself [107], downregulation of poly-
cystin-2 and subsequent impaired ciliary trafficking of the
AKAP complex may also contribute to the elevation of
cAMP levels [106]. PDE1 isoforms (PDE1a, PDE1b, and
PDE1c) are expressed to high levels in the kidney cells
[108]. Importantly, these PDE isoforms are also regulated
by cytosolic Ca2?, which in ADPKD would result in
decreased PDE activity and a higher cAMP concentration
[42]. An additional mechanism that could be important in
ADPKD is cAMP production related to Ca2?-store deple-
tion and STIM1 translocation [109]. These data are
indicative of a mechanism of store-operated cAMP sig-
naling, in which lowering of the Ca2? concentration in the
ER led to recruitment of ACs through a process involving
STIM1 [109]. This mechanism was also found in polycy-
stin-2-defective cholangiocytes, where polycystin-2 was
suggested to play a role in SOCE activation and in inhib-
iting the STIM-dependent activation of AC6 [110]. In view
of the observation that polycystin-1 expression impairs
translocation of STIM to the plasma membrane, this
mechanism could also link polycystin-1 defects to
increased cAMP signaling in ADPKD [41, 96].
Effects on B-Raf-extracellular signal-regulated kinase
(ERK) signaling and cell proliferation (Fig. 2)
In general, cystic epithelia in ADPKD have high levels of
cAMP and also of mitogen-activated protein kinase
(MAPK) activity. This signaling pathway, involving
cAMP-dependent PKA, stimulates the proliferation of cells
from ADPKD cysts, but not cells from normal human
kidney [111–113]. In normal cells, cAMP via PKA-medi-
ated phosphorylation inhibits the MAPK pathway by
blocking the activation of Raf-1 (Raf-C). In cystic cells,
however, cAMP signaling is changed, an effect which is
attributed to the low cytosolic Ca2? concentration [114,
115]. Ca2? restriction was associated with an elevation in
B-Raf protein levels. In these conditions, cAMP stimulates
B-Raf/MEK/ERK signaling in a sarcoma (Src)- and Ras-
dependent manner. Moreover, the activity of AKT, a neg-
ative regulator of B-Raf, was decreased by Ca2? restriction.
Inhibition of AKT or PI3-K also allowed cAMP-dependent
activation of B-Raf and ERK at normal Ca2? levels. These
results suggest that Ca2? restriction causes an inhibition of
the PI3-K/AKT pathway, which relieves the inhibition of
B-Raf to allow the cAMP growth-stimulated phenotypic
switch [112, 114]. The steady-state cytosolic Ca2? con-
centration was found to be 20 nM lower in cyst-derived
ADPKD cells compared with normal cells. Elevation of the
cytosolic Ca2? concentration in ADPKD cells increased
AKT activity and blocked cAMP-dependent B-Raf and
ERK activation. Thus, an increase in the cytosolic Ca2?
concentration was able to restore the normal anti-mitogenic
response to cAMP [115], while Ca2?-channel inhibition by
verapamil accelerated polycystic kidney-disease progres-
sion [116]. On the other hand, it was found that down-
regulation of polycystin-1 using RNA interference [117] or
expression of the dominant-negative polycystin-1 C-termi-
nus [95, 118] resulted in an increase in basal Ca2?
concentration. The differential effects of polycystin-1
expression on the cytosolic Ca2? concentration and down-
stream effects could reflect the use of different cell types
such as immortalized cells versus primary cells [117].
Effects on mammalian target of rapamycin (mTOR)
signaling (Fig. 2)
Cyst-lining epithelial cells exhibit higher levels of mTOR
signaling as compared to normal epithelial cells [119].
mTOR is a serine/threonine protein kinase that provides
catalytic activity for two distinct multiprotein complexes
(mTORC1 and mTORC2). mTORC1 is a metabolic sensor
and its activation promotes cell growth and cell prolifera-
tion. The effects of mTORC2 include modulation of cell
survival, cytoskeletal organization, and cell polarity [120].
Hyperactivity of mTORC1 and possibly also of mTORC2,
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contributes to cyst formation [121]. Tuberin, the protein
product of Tsc2, in a complex with hamartin, the product of
Tsc1, is the primary negative regulator of mTORC1. Tub-
erin is a GTPase-activating protein (GAP), which regulates
Rheb, a small G-protein belonging to the Ras superfamily.
Hamartin and tuberin form a heterodimer, which converts
Rheb-GTP to the inactive Rheb-GDP. Rheb is an activator
of mTORC1 and conversion of Rheb to the GDP-bond form
inactivates the mTORC1 pathway [120–123]. The tuberin–
hamartin complex is a nodal point for several polycystin-
dependent pathways. The cytoplasmic tail of polycystin-1
interacts with tuberin. This may occur via direct interaction
with tuberin [119] or indirectly via ERK-dependent phos-
phorylation and inactivation of the tuberin complex [124].
A prominent activation of the ERK pathway together with
cystogenesis was found upon inactivation of the Pkd1 gene
in conditional knock-out mice [125]. The regulation may,
however, be more complex as tuberin has been reported to
be phosphorylated by at least nine distinct protein kinases
[126]. Among these are multiple pathways that may be
linked to proper functioning of polycystins and some of
these are clearly linked to Ca2? (Fig. 2). As explained
above, a potential link with Ca2? and cAMP may occur via
B-Raf/ERK signaling. The lower Ca2? levels in cystic cells
would together with the increased cAMP concentration lead
to activation of B-Raf/ERK and subsequent mTORC1 sig-
naling [42, 114, 115]. Another mechanistic input of
polycystins on mTORC1 is via ciliar activation of liver
kinase B1 (LKB1), which, like the polycystins, is localized
in the basal bodies of primary cilia [127]. LKB1 activates
AMP-activated protein kinase (AMPK), which then acti-
vates tuberin with subsequent negative regulation of
mTORC1. This cilium-mediated effect on mTOR was,
however, found to be independent of flow-induced Ca2?
transients or AKT [127]. Next to LKB1, however, AMPK
activity is also directly linked to the cytosolic Ca2? con-
centration by calmodulin-dependent protein kinase kinase ß
(CaMKKb) [128]. The link between the changed cytosolic
Ca2? concentration in cystic cells and mTORC1 via
CaMKKb-dependent regulation of AMPK is, however, not
yet established. A relation between AMPK activity and cyst
formation was, however, found by using metformin, a drug
[Ca2+]i [cAMP]






















Fig. 2 Signaling pathways that relate disturbed polycystin-mediated
Ca2? signaling to cell proliferation. Defects in polycystin functions
generally lead to a decrease in the cytosolic Ca2? concentration
([Ca2?]i). This results in an increase in cAMP concentration, probably
via changes in Ca2?-dependent phosphodiesterase or Ca2?-dependent
adenylate-cyclase activity (not shown). The Ca2?-cAMP link is
represented by the box. In the presence of low [Ca2?]i, cAMP
becomes pro-proliferative via activation of the Src/Ras/B-Raf/MEK/
ERK pathway. Ca2? restriction causes decreased PI3-K/AKT signal-
ing, which relieves the inhibition of B-Raf. Activation of growth-
factor receptors with tyrosine-kinase activity (GFR) also contributes
to the stimulation of MAPK/ERK signaling and cell proliferation.
Polycystin-1 dysfunction thus upregulates the MAPK/ERK pathway,
which results in inactivation of the tuberin complex and increased
mTORC1. Cytoplasmic Ca2? also regulates the mTOR pathway via
CaMKKß and AMPK (the question mark indicates that the occurrence
of this mechanism was not yet explored in cystic cells). The
deregulated Ca2? signaling switches on canonical Wnt signaling,
which activates mTOR via inhibiting GSK3 phosphorylation of
tuberin. Another link to cell proliferation may depend on the
activation of Ca2? oscillations and subsequent effects on gene
transcription and cyclins via Ca2?-dependent NFAT or via protein
kinase Ca (PKCa) signaling. Boxed areas indicate mechanisms not
shown in detail. Dotted arrows indicate still-unresolved mechanisms.
GFR growth-factor receptor
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in wide clinical use as a pharmacological activator of
AMPK [129]. Stimulation of AMPK activity by metformin
resulted in inhibition of the mTOR pathway and significant
arrest of cystic growth in in vitro and ex vivo models of
renal cystogenesis [129].
Additional pathways may converge on mTOR signaling
in a Ca2?-dependent way. Wnt signaling, which was shown
to be regulated by polycystin-1 [130], can activate a
ß-catenin-dependent (canonical) and a ß-catenin-indepen-
dent (non-canonical) pathway. In addition, a Wnt-Ca2?
pathway influences both canonical and non-canonical
pathways [131]. Inversin, a ciliar protein, functions as a
molecular switch between the different Wnt signaling
pathways [132]. It can be speculated that ciliary events as
flow-induced Ca2? influx can switch off the canonical and
activate the non-canonical pathway [42]. Over-activation
of canonical Wnt and subsequent over-production of acti-
vated ß-catenin would promote the polycystic phenotype
[133]. This is further supported by many observations
showing a link between disturbed polycystin function and
enhanced activity of Wnt signaling [130, 134–136]. In
addition, the Wnt pathway is also able to act on mTOR via
AMPK and GSK3 [137] (Fig. 2). Tuberin was reported to
be a physiological substrate of GSK3, which required
priming phosphorylation by AMPK. Canonical Wnt then
activates mTOR via inhibiting GSK3 phosphorylation of
tuberin [137]. Moreover, GSK3ß was shown to be activated
by polycystin-1 [138]. In ADPKD, disturbed polycystin-1
function and disturbed Ca2? signaling may thus both
contribute to a GSK3-dependent increase in mTOR activity
[124].
Effects on cell proliferation and apoptosis (Figs. 2, 3)
Kidneys from ADPKD patients have high levels of apop-
tosis in addition to increased cellular proliferation [139–
141]. This dysregulation of both apoptosis and proliferation
may represent a general mechanism for cyst growth and
remodeling [140, 142], and the imbalance between pro-
apoptotic and pro-proliferative factors was proposed to be
critical for the development of cystic kidney disease [143–
145]. Different signaling pathways may be implicated in the
abnormal cell-cycle progression. Polycystin-1 activates the
JAK-STAT pathway, thereby up-regulating p21 (waf1), an
inhibitor of cyclin-dependent kinase (CDK), and thereby
inducing cell-cycle arrest in G0/G1. This process requires
polycystin-2 as an essential cofactor [146]. A decrement of
p21 in cystic kidneys as compared to non-cystic kidneys
was demonstrated in humans and rat models [147]. Ros-
covitine, which has been shown to arrest progression in a
murine model of polycystic kidney disease, increases p21
levels and decreases renal tubular epithelial-cell prolifera-
tion [147, 148]. Renal tubular epithelial cells exposed to
‘‘low’’ concentrations of roscovitine showed minimal
apoptosis in association with markedly increased levels of
the anti-apoptotic protein p21, and these cells became
senescent. Conversely, cells exposed to ‘‘high’’ levels of
roscovitine became apoptotic [149]. Tubular-cell apoptosis
occurs in most animal models of ADPKD like the SBM
mouse [150, 151] and the Han:SPRD rat model [152], as
well as in kidneys from ADPKD patients [139–141]. Mice
deficient in the anti-apoptotic Bcl-2 gene develop poly-
cystic kidney disease characterized by dilated proximal and
distal tubular segments and hyper-proliferation of the epi-
thelium and interstitium [153, 154]. While ablation of the
pro-apoptotic Bim prevented the development of polycystic
kidney disease in mice deficient in Bcl-2 [155], this was not
the case in polycystin-1-deficient mice. This indicates that
loss of Bcl-2 or loss of polycystin-1 elicit polycystic kidney
disease through different mechanisms [156]. Similarly,
deletion of another anti-apoptotic gene, the AP2ß tran-
scription factor, in AP2ß-/- mouse resulted in polycystic
kidney disease with concomitant down-regulation of anti-
apoptotic Bcl-2-family proteins and massive apoptotic cell
death [157]. A direct cause-and-effect relationship between
cyst formation and apoptosis was demonstrated in
Han:SPRD rats using caspase inhibitors. Caspase inhibition
was found to reduce tubular apoptosis and proliferation and
to slow disease progression in polycystic kidney disease
[158]. A marked increase in caspase-3 and -7 activity has
been reported in the Han:SPRD rat [143, 159, 160], and
targeted caspase-3-gene deletion prolongs survival [161]. In
the SBM mouse that overexpresses the proto-oncogen
c-myc, both proliferative and apoptotic indexes were highly
increased, reflecting a critical imbalance in c-myc regula-
tion of the opposing processes of cell proliferation and
apoptosis [162]. Overexpression of c-myc was found in
cystic tissue and is supposed to play a role in the dysregu-
lation of both proliferation and apoptosis in ADPKD [140,
162–165].
Ca2? signaling is implicated in the phenotypic feature of
ADPKD cells showing elevated rates of both proliferation
and apoptosis, but the downstream mechanisms are not
fully resolved. It was found that polycystin-1 induces
resistance to apoptosis and normal tubulogenesis through
the PI3-K/AKT pathway [166] (Fig. 3). These data are
consistent with observations that loss of polycystin-1
function results in changes in cytosolic Ca2? concentration,
down-regulation of PI3-K/AKT and activation of B-Raf/
ERK in ADPKD cysts [114]. As already outlined above,
the disturbed intracellular Ca2? signaling could be a pri-
mary event in ADPKD and may be responsible for the
switch to a proliferative phenotype with an elevation in
B-Raf protein levels and cAMP-stimulated, Ras-dependent
activation of B-Raf and ERK [114, 115]. Also, a PKD2
transgenic7 mouse model resulted in renal-cys formation
Polycystins and cellular Ca2? signaling 2705
123
via B-Raf signaling, probably by acting as a dominant
negative modulator for polycystin function and down-
stream Ca2? signals [167]. Pkd2?/- vascular smooth-
muscle cells also have an abnormal phenotype with a
defective Ca2? signaling with decreased levels of the
cytosolic Ca2? and an increased cellular cAMP concen-
tration, which is probably underpinning increased
proliferation and apoptosis [168]. The low cytosolic Ca2?
concentration apparently provoked increased proliferation
in these vascular smooth-muscle cells but the effect in this
cell type was independent of cAMP/B-Raf signaling [168].
A divergent mechanism was proposed, in which dis-
turbed polycystin-1 function affected cell proliferation by
an increase in intracellular Ca2? signaling in the form of
activation of Ca2? oscillations [117] (Fig. 2). Serum treat-
ment of HEK293 cells with down-regulated polycystin-1 or
of cystic cells expressing mutated polycystin-1 resulted in
increased oscillatory activity of the cytosolic Ca2? con-
centration which led to activation of cell proliferation. The
proposed mechanism involved non-capacitative Ca2? entry
(NCCE), which was proposed to be negatively regulated by
polycystin-1. The loss of polycystin-1 resulted in NCCE
activation and increased Ca2? oscillations. The downstream
effects were related to activation of the calcineurin/nuclear
factor of activated T cells (NFAT) pathway. The explana-
tion could be that Ca2? oscillations rather than the basal
Ca2? concentration are crucial for activation of the NFAT-
dependent cell proliferation [117].
Another important factor, particularly for the increased
apoptosis in ADPKD, could be the regulation of the ER
Ca2? content by polycystins [84] (Fig. 3). The ER Ca2?
content is determined by the activity of Ca2? pumps and by
the Ca2?-leak rate via different pathways. The resulting ER
Ca2? load is a primary determinant of the extent of ER-to-
mitochondrial Ca2? transfer and pro-apoptotic Ca2? sig-
naling [84]. Polycystin-2 in the ER may act as a Ca2?-leak
pathway and in this way control the degree of ER Ca2?
filling [85]. Normal polycystin-2 functioning would then
reduce Ca2? release from the ER in response to apoptotic
stimuli, and conversely, its loss in ADPKD would lead to
an increased apoptosis [85]. Although this mechanism may
provide a simple molecular explanation for the increased
apoptosis rate in ADPKD upon loss of polycystin-2 func-
tion, the situation may be more complex. As discussed
above, polycystin-2 activity and its modulation of ER Ca2?
are probably tightly regulated by many other cellular fac-
tors and interacting proteins. Not only is polycystin-2 a
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Fig. 3 Signaling pathways relating disturbed polycystin-mediated
Ca2? signaling to apoptotic cell death. Disruption of PC1 function
leads to a phenotype with low intracellular Ca2? concentration and
high cAMP concentration that showed a mitogenic response towards
cAMP and down-regulation of PI3-K/AKT. This provokes a profound
remodeling of the relation between Ca2? release and Ca2? influx via
an IP3R/PC2/STIM1 protein complex. Decreased AKT signaling
would strengthen the IP3R-PC2 interaction and lead to increased
IICR, translocation of STIM1 to the plasma membrane, and refilling
of the ER via SOCE. AKT can also directly phosphorylate the IP3R
thereby inhibiting its activity. A decreased AKT activity in cystic
cells would thereby relieve the inhibition of the IP3R and contribute to
the increase in IICR. PC2 can function as an ER Ca2?-leak channel
and a loss of function would therefore increase the ER Ca2? content
and IICR. The increased IICR via these different mechanisms
ultimately leads to increased Ca2? transfer from the ER to the
mitochondria. Mitochondrial Ca2? overload is a very important
determinant of Ca2?-dependent apoptosis. Boxed areas indicate
mechanisms not shown in detail. Dotted arrows indicate still
unresolved mechanisms. IP3R-P: IP3R phosphorylated by AKT
(S2681 in IP3R1)
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intracellular Ca2?-release channels, IP3Rs and RyRs, and
with various plasma-membrane TRP channels. Polycystin-
1 controls the activity of polycystin-2 directly and also in
an indirect way via PI3-K/AKT signaling. Decreased PI3-
K/AKT signaling in ADPKD would thereby lead to a
profound remodeling with increased IICR and SOCE
(Fig. 3). This results from activation of Ca2? release via
polycystin-2, but also from a higher IP3R activity resulting
from the relieve of the brake imposed by AKT-mediated
phosphorylation [169]. Increased IICR, particularly at the
contact sites of the ER and mitochondria, constitutes a
strong apoptotic signal [84, 170].
In conclusion, disturbed or remodeled cellular Ca2?
signaling is clearly a very early event in the development of
the cystic phenotype of renal cells. This phenotype is
characterized by a concomitant activation of both cell
proliferation and apoptotic cell death. Despite the increased
proliferation as an invariable component of cystogenesis,
there is seldom progression towards renal carcinoma [171].
Overexpression of polycystin-1 provoked apoptosis in dif-
ferent cancer cell lines, and it is tempting to speculate that
polycystins, by controlling the balance between prolifera-
tion and cell death, may play a role in preventing malignant
transformation [171]. ADPKD epithelial cells are thereby
characterized by a modest degree of cell proliferation
together with a proportional increase in apoptosis [139, 140,
146, 153, 157, 172]. Both polycystins are closely involved
in cellular Ca2? signaling by direct or indirect interaction
with many proteins of the cellular Ca2? toolkit. It becomes
increasingly evident that polycystin dysfunctions lead to a
profound remodeling of cellular Ca2? signaling and pro-
voke changes in the spatio-temporal modes of Ca2?
signaling. This could lead to changes in the occurrence of
different Ca2?-signaling microdomains located at the cilia
or at the ER-mitochondria junctions, and it could lead to
oscillatory Ca2? signals that may evoke nuclear responses.
It will be a challenge for future research to experimentally
detect the subcellular Ca2?-signaling microdomains and to
identify their downstream responses that result in the
increased proliferation and increased apoptosis responses,
which are characteristic for the cystic phenotype.
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